

~~167~~¹⁶⁷. The composition of claim ~~161~~¹¹ wherein the pharmaceutically acceptable salt is a calcium salt.

~~168~~¹⁶⁸. The heparinic mucopolysaccharide fractions of claim ~~137~~¹⁶⁸ wherein the lower molecular weight fractions are free of nucleic acids.--

REMARKS

The additional claims are drawn to the method of use of the compositions of the invention and the therapeutic compositions. Claims 128 through 133 which were drawn to such subject matter have been cancelled

The present claims are principally based on page 40 and 41 which discloses the various ranges of dosages. Claim 168 is based on page 30 which discloses that the major part of the nucleic acids were removed from the lower molecular weight fraction.

In accordance with the Examiner's request and extra copy of claims 108-136 is attached to this Amendment.

With respect to the prior art filed, it is submitted that none of it discloses or teaches the particular subject matter claimed herein.


From Anderson et al, it is apparent which portions of the heparin material were collected and which were not (Fig. 1, p. 579). Barrowcliffe et al separates conventional heparin and collects fractions of molecular weight in the range of 6,000 to 30,000 (p. 29). Johnson et al investigates four different heparin preparations with respect to anti-Xa activity which is found to be of substantially the same magnitude in LMW and HMW preparations.

There is no teachings or disclosure of the claimed compositions having the particular parameters set forth in the claims, nor of their particularly advantageous therapeutic properties. The compositions have significant overall anticoagulation activity, yet lower than that of natureal heparin, and a high antithrombotic activity.

It should be noted that one skilled in the art could not have foretold from the knowledge of the art and of heparin's properties at the time the invention was made, whether the anticoagulation activity of a heparinic composition should be increased or at least maintained at the safe level of that of heparin.

Favorable action is respectfully requested.

Respectfully submitted,


GERARD J. WEISER
Reg. No. 19,763
WEISER & STAPLER
Attorney for Applicant

WEISER & STAPLER
1510 Two Penn Center Plaza
Philadelphia, PA 19102
(215) 563-6600

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on 4-17-87


Signature

4-17-87
Date